View More Recent Stories

Sep 18, 2024 05:17PM Syndax (SNDX) and Incyte (INCY) Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo
Aug 16, 2024 06:42AM Syndax Pharmaceuticals (SNDX) PT Raised to $45 at H.C. Wainwright
Aug 15, 2024 10:35AM TD Cowen Reiterates Buy Rating on Syndax Pharmaceuticals (SNDX)
Aug 15, 2024 09:27AM Syndax Pharmaceuticals (SNDX) PT Raised to $34 at Citi
Aug 15, 2024 06:25AM Syndax Pharmaceuticals (SNDX) PT Raised to $31 at BofA Securities
Aug 12, 2024 07:02AM Syndax Pharmaceuticals (SNDX) Announces Publication in the Journal of Clinical Oncology of Data from the Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia
Aug 1, 2024 04:49PM Syndax Pharmaceuticals (SNDX) Tops Q2 EPS by 11c
Jul 30, 2024 05:19AM Syndax Pharmaceuticals (SNDX) PT Lowered to $30 at BofA Securities
Jul 29, 2024 10:53AM Syndax Pharmaceuticals (SNDX) PT Lowered to $40 at Stifel
Jul 29, 2024 07:01AM Syndax Pharmaceuticals (SNDX) Announces PDUFA Action Date Extension for Revumenib NDA for Relapsed or Refractory KMT2Ar Acute Leukemia
Jun 28, 2024 05:08AM Jefferies Starts Syndax Pharmaceuticals (SNDX) at Buy
Jun 26, 2024 02:59AM Syndax Pharmaceuticals (SNDX) PT Raised to $42 at Stifel
Jun 14, 2024 07:00AM Syndax Pharmaceuticals (SNDX) Updated Positive Data from BEAT AML and AUGMENT-102 Phase 1/2 Combination Trials of Revumenib
View More Recent Stories